Corvus Pharmaceuticals, Inc. — Director's Dealing 2016

Mar 22, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Corvus Pharmaceuticals, Inc. (CRVS)
CIK: 0001626971
Period of Report: 2016-03-22

Reporting Person: LEA LEIV (Chief Financial Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, $0.0001 par value	156645	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Convertible Preferred Stock	$0.00		Common Stock (42608)		Indirect

Footnotes

F1: A portion of these shares is subject to a right of repurchase held by the Issuer.

F2: These shares are held by Leiv Lea and Deborah Karlson, Trustees of the Karlson Lea Family Trust UTA dated February 11, 1998 (the "Karlson Lea Trust"). Mr. Lea has shared voting, investment and dispositive power over the shares held by the Karlson Lea Trust.

F3: The Series A Convertible Preferred Stock and Series B Convertible Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of Issuer's initial public offering.

F4: The expiration date is not relevant to the conversion of these securities.